JPWO2011019072A1 - うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体 - Google Patents

うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体 Download PDF

Info

Publication number
JPWO2011019072A1
JPWO2011019072A1 JP2011526785A JP2011526785A JPWO2011019072A1 JP WO2011019072 A1 JPWO2011019072 A1 JP WO2011019072A1 JP 2011526785 A JP2011526785 A JP 2011526785A JP 2011526785 A JP2011526785 A JP 2011526785A JP WO2011019072 A1 JPWO2011019072 A1 JP WO2011019072A1
Authority
JP
Japan
Prior art keywords
acid
depression
alanine
biomarker
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526785A
Other languages
English (en)
Japanese (ja)
Inventor
則行 川村
則行 川村
幸作 篠田
幸作 篠田
由明 大橋
由明 大橋
貴正 石川
貴正 石川
基 佐藤
基 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Metabolome Technologies Inc
Original Assignee
Human Metabolome Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Metabolome Technologies Inc filed Critical Human Metabolome Technologies Inc
Publication of JPWO2011019072A1 publication Critical patent/JPWO2011019072A1/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011526785A 2009-08-12 2010-08-12 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体 Pending JPWO2011019072A1 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009187521 2009-08-12
JP2009187521 2009-08-12
JP2009291029 2009-12-22
JP2009291029 2009-12-22
PCT/JP2010/063713 WO2011019072A1 (ja) 2009-08-12 2010-08-12 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012121097A Division JP5372213B2 (ja) 2009-08-12 2012-05-28 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体

Publications (1)

Publication Number Publication Date
JPWO2011019072A1 true JPWO2011019072A1 (ja) 2013-01-17

Family

ID=43586246

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011526785A Pending JPWO2011019072A1 (ja) 2009-08-12 2010-08-12 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
JP2012121097A Active JP5372213B2 (ja) 2009-08-12 2012-05-28 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
JP2013191911A Active JP5859502B2 (ja) 2009-08-12 2013-09-17 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012121097A Active JP5372213B2 (ja) 2009-08-12 2012-05-28 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
JP2013191911A Active JP5859502B2 (ja) 2009-08-12 2013-09-17 うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体

Country Status (6)

Country Link
US (2) US8951739B2 (https=)
EP (1) EP2466312B1 (https=)
JP (3) JPWO2011019072A1 (https=)
CN (2) CN102667485B (https=)
DK (1) DK2466312T3 (https=)
WO (1) WO2011019072A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731860B2 (ja) * 2011-03-11 2015-06-10 テルモ株式会社 腹膜組織の傷害検出方法
CN106399458A (zh) * 2011-11-10 2017-02-15 福满代谢组技术有限公司 乙醇胺磷酸酯的测定方法
PT3598971T (pt) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
JP6211283B2 (ja) * 2013-03-29 2017-10-11 ヒューマン・メタボローム・テクノロジーズ株式会社 脳症の検出方法
CN103630678A (zh) * 2013-03-29 2014-03-12 中国科学院城市环境研究所 男性不育的生物标志物及其应用
EP2799878A1 (en) * 2013-05-03 2014-11-05 SALION GmbH In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant using kynurenine as a marker.
HK1221053A1 (zh) * 2013-05-23 2017-05-19 艾弗诺泰普有限责任公司 用於保持或改善健康的方法和系统
US20150056605A1 (en) * 2013-08-21 2015-02-26 Purdue Research Foundation Identification of blood based metabolite biomarkers of pancreatic cancer
CN103529159B (zh) * 2013-10-18 2015-05-13 哈尔滨医科大学 一种血液非靶标代谢组学研究样品的前处理方法
EP3190413B1 (en) * 2014-09-26 2021-08-11 Human Metabolome Technologies, Inc. Method for predicting depression treatment drug alternatives
KR101604074B1 (ko) * 2015-05-14 2016-03-17 한국과학기술원 대사체 프로파일링을 이용한 정신질환의 진단 또는 진행성 예측 방법 및 바이오마커
CN105177117A (zh) * 2015-07-03 2015-12-23 张理义 重症抑郁障碍生物标记物、筛选方法及试剂盒
CN104991010B (zh) * 2015-07-29 2017-10-13 中国药科大学 一种区分乳腺癌亚型生物标志物的组合物
US20180348195A1 (en) * 2015-11-12 2018-12-06 Kyushu University, National University Corporation Biomarker for diagnosing depression and use of said biomarker
CN105486778B (zh) * 2016-01-25 2017-11-03 齐炼文 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物
CN105445408B (zh) * 2016-01-25 2018-06-12 齐炼文 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物
WO2017210097A1 (en) * 2016-06-02 2017-12-07 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
WO2018117064A1 (ja) * 2016-12-21 2018-06-28 国立大学法人徳島大学 うつ状態を呈する疾患を検査する方法
US11869633B2 (en) * 2017-12-15 2024-01-09 The Board Of Trustees Of The University Of Illinois Analytics and machine learning framework for actionable intelligence from clinical and omics data
CN111727038B (zh) * 2018-01-17 2025-05-13 南安普顿大学 肌肉减少症和nad缺乏的风险预测及分级方法
CN112689755A (zh) * 2018-09-11 2021-04-20 梅塔博隆股份有限公司 用于检测和定量微生物区系相关代谢物的质谱测定法
JPWO2020122231A1 (ja) 2018-12-13 2021-10-21 キッコーマン株式会社 エタノールアミンリン酸の定量方法、定量用のオキシドレダクターゼ、定量用組成物、定量用キット及び定量用センサー
CA3133221A1 (en) * 2019-03-13 2020-09-17 Duke University Methods and compositions for diagnosing depression
CN110286191A (zh) * 2019-06-27 2019-09-27 山西大学 一种生物样品中代谢标志物检测方法及应用
EP4042165B1 (en) * 2019-10-11 2023-11-15 Société des Produits Nestlé S.A. 2-methylbutyrate, a biomarker for improvements of mood disorders
GB201916185D0 (en) * 2019-11-07 2019-12-25 Randox Laboratories Ltd Biomarker of drug-induced cellular toxicity and depression
BR112022025317A2 (pt) * 2020-06-15 2023-01-03 Univ Basel Método de dosagem de um empatógeno/entactógeno no tratamento de pacientes; método para determinar uma dose de um empatógeno/entactógeno com base no peso corporal, sexo e atividade de cyp2d6; método para refinar a dosagem de um empatógeno/entactógeno; método para predizer a dosagem futura com um empatógeno/entactógeno; método para avaliar a viabilidade de pacientes para receber um empatógeno/entactógeno como tratamento; e método para otimizar o tratamento com empatógeno/entactógeno em um paciente
WO2021256503A1 (ja) 2020-06-17 2021-12-23 キッコーマン株式会社 エタノールアミンリン酸の定量方法、定量用のオキシドレダクターゼ、定量用組成物、定量用キット、センサーチップ、及びセンサー
CN111693624B (zh) * 2020-06-22 2021-07-09 南京市中医院 一种与儿童多发性抽动症诊断相关的血浆代谢标志物在制备儿童多发性抽动症诊断试剂盒中的应用
CN112630311B (zh) * 2020-07-09 2023-07-18 深圳云合医药科技合伙企业(有限合伙) 用于检测情感障碍的代谢标记物和试剂盒及使用方法
US20240012008A1 (en) * 2020-10-30 2024-01-11 The Regents Of The University Of California Compositions and methods for diagnosing and treating patients with a history of early life adversity
CN114544826B (zh) * 2020-11-24 2023-12-08 重庆医科大学 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途
CN114624345B (zh) * 2020-12-10 2023-06-06 中国科学院大连化学物理研究所 一种联合生物标志物及其应用
US11854684B2 (en) * 2020-12-29 2023-12-26 Kpn Innovations, Llc. Methods and systems for nourishment refinement using psychiatric markers
US20250121014A1 (en) * 2021-09-17 2025-04-17 Societe Des Produits Nestle S.A. Method for detecting and/or quantifying mood disorder and/or improvements of the mood disorder status using butyrate as biomarker and improved methods and compositions thereof
US20240393304A1 (en) * 2021-09-28 2024-11-28 Societe Des Produits Nestle S.A. Method for detecting and/or quantifying mood disorder and/or improvements of the mood disorder status using trigonelline as biomarker and improved methods and compositions thereof
US11754536B2 (en) 2021-11-01 2023-09-12 Matterworks Inc Methods and compositions for analyte quantification
US12100484B2 (en) 2021-11-01 2024-09-24 Matterworks Inc Methods and compositions for analyte quantification
JP7819901B2 (ja) * 2021-11-04 2026-02-25 国立大学法人九州大学 ひきこもりのバイオマーカー、ひきこもり識別支援方法
CN114176581A (zh) * 2021-12-06 2022-03-15 重庆邮电大学 基于体液中l-酪氨酸含量的抑郁情绪检测装置
CN116429952B (zh) * 2023-03-27 2024-02-02 深圳市第二人民医院(深圳市转化医学研究院) 一种抑郁症标志物及其在抑郁症诊断中的应用、评估装置
CN116809027B (zh) * 2023-05-18 2026-01-27 复旦大学附属中山医院 一种用于捕获外泌体的异质性复合材料及其制备方法和应用
CN116990498B (zh) * 2023-09-28 2024-08-09 山东大学齐鲁医院 血浆色氨酸代谢物在儿童偏头痛诊断中的应用
CN117590005A (zh) * 2024-01-15 2024-02-23 中国疾病预防控制中心环境与健康相关产品安全所 空气污染致抑郁的代谢标志物组合及其筛选方法和应用
WO2025163640A1 (en) * 2024-01-31 2025-08-07 Sheba Impact Ltd. Ai based clinical decision support system (cdss) for mental health
CN118566488B (zh) * 2024-04-10 2026-02-27 合肥歆智医疗器械有限公司 抑郁症检测用试剂组合、制造方法、检测系统及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006338A1 (en) * 2007-06-29 2009-01-08 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
JP2009524450A (ja) * 2006-01-24 2009-07-02 カーディアック ペースメイカーズ， インコーポレイテッド うつ病の検出および治療装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314144A (en) * 1996-02-02 1999-04-29 Smithkline Beecham Corp Computerised identification of at risk patients diagnosed with depression
GB9826899D0 (en) * 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
WO2004080312A1 (ja) 2003-03-14 2004-09-23 Seizaburo Arita うつ病の診断方法
EP2146209B1 (en) 2005-04-06 2011-11-16 University of Antwerp Neurodegenerative markers for Alzheimer's disease
JP2007024822A (ja) 2005-07-21 2007-02-01 Aska Pharmaceutical Co Ltd 男性の更年期又はうつ病の鑑別方法
GB0524609D0 (en) * 2005-12-02 2006-01-11 Univ Cambridge Tech Methods of monitoring and diagnosing psychotic disorders and of identifying biomarkers for psychotic disorders
US20080281531A1 (en) 2007-03-15 2008-11-13 Kazuhito Rokutan Method for Diagnosing Depression
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒
JP2009092550A (ja) 2007-10-10 2009-04-30 Japan Health Science Foundation うつ病またはうつ状態の同定方法
JP2009187521A (ja) 2008-01-08 2009-08-20 Yaskawa Electric Corp 位置指令作成方法及び位置指令作成装置
JP2009291029A (ja) 2008-05-30 2009-12-10 Yazaki Corp コルゲートチューブ配索部材

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524450A (ja) * 2006-01-24 2009-07-02 カーディアック ペースメイカーズ， インコーポレイテッド うつ病の検出および治療装置
WO2009006338A1 (en) * 2007-06-29 2009-01-08 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011000200; Ｙａｓｕｓｈｉ Ｅｎｏｋｉｄｏ: 'Ｃｙｓｔａｔｈｉｏｎｉｎｅ beta-ｓｙｎｔｈａｓｅ， ａ ｋｅｙ ｅｎｚｙｍｅ ｆｏｒ ｈｏｍｏｃｙｓｔｅｉｎｅ ｍｅｔａｂｏｌｉｓｍ， ｉｓ ｐｒｅｆｅｒｅｎｔｉａｌｌｙ ｅｘｐｒｅｓｓｅｄ ｉｎ' Ｔｈｅ ＦＡＳＥＢ Ｊｏｕｒｎａｌ ｖｏｌ．１９, 200511, Ｐ．１８５４-１８５６, ＦＡＳＥＢ *
JPN6012013843; Ａ． Ｍ． ＢＥＲＴＯＬＩＮＩ: 'Ｄｅｆｉｃｉｔ ｄｉ ａｍｉｎｏａｃｉｄｉ ｐｒｅｃｕｒｓｏｒｉ ｄｉ ｍｅｄｉａｔｏｒｉ ｃｈｉｍｉｃｉ ｅ ｄｉ ｃｒｅａｔｉｎａ ｎｅｌｌ'ａｎｚｉａｎｏ' Ｍｉｎｅｒｖａ Ｍｅｄｉｃａ Ｖｏｌ．７２／Ｎｏ．３２, 19810908, ２１５７-２１６０, Ｅｄｉｚｉｏｎｉ Ｍｉｎｅｒｖａ Ｍｅｄｉｃａ *

Also Published As

Publication number Publication date
JP2012211908A (ja) 2012-11-01
US9442121B2 (en) 2016-09-13
US20120282592A1 (en) 2012-11-08
CN102667485A (zh) 2012-09-12
CN102667485B (zh) 2015-04-22
CN104777314B (zh) 2017-01-04
US8951739B2 (en) 2015-02-10
US20150126623A1 (en) 2015-05-07
JP2014013257A (ja) 2014-01-23
DK2466312T3 (da) 2020-01-13
EP2466312A1 (en) 2012-06-20
JP5372213B2 (ja) 2013-12-18
JP5859502B2 (ja) 2016-02-10
EP2466312B1 (en) 2019-10-16
WO2011019072A1 (ja) 2011-02-17
CN104777314A (zh) 2015-07-15
EP2466312A4 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
JP5372213B2 (ja) うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
Ashton et al. No association of salivary total tau concentration with Alzheimer's disease
EP3028049B1 (en) Diagnostic tools for alzheimer's disease
JP2013525801A (ja) 自閉症の代謝バイオマーカー
CN107667293A (zh) 用于阿茲海默氏病的诊断工具
JP6870679B2 (ja) アルツハイマー型認知症の将来の発症リスクの評価方法
Wormwood et al. Salivary proteomics and biomarkers in neurology and psychiatry
WO2018008764A1 (ja) 軽度認知障害又はアルツハイマー型認知症の評価方法
JP2014521928A (ja) アルツハイマー病のリスクの増加を診断するための方法
US9977036B2 (en) Diagnostic markers for multiple sclerosis
González-Quevedo et al. Increased serum S-100B and neuron specific enolase—Potential markers of early nervous system involvement in essential hypertension
Monteleone et al. Search of brain-enriched proteins in salivary extracellular vesicles for their use as mental disease biomarkers: A pilot study of the neuronal glycoprotein M6a
Zhu et al. Serum high-sensitivity C-reactive protein levels are positively associated with cognitive impairments in patients with first-episode schizophrenia
Mo et al. Association of cerebrospinal fluid zinc-α2-glycoprotein and tau protein with temporal lobe epilepsy and related white matter impairment
US20240142471A1 (en) Test for mild cognitive impairment
WO2018117064A1 (ja) うつ状態を呈する疾患を検査する方法
WO2022039191A1 (ja) 軽度認知障害の試験方法、軽度認知障害の試験試薬、および軽度認知障害の治療薬候補物質のスクリーニング方法
JP7226732B2 (ja) 尿中腫瘍マーカーによるがん検出方法、キット及び装置
WO2010005077A1 (ja) パーキンソン病の疾患関連たんぱく質およびその使用
JP2024029191A (ja) 認知症又はそのリスクの検査方法
JP6211283B2 (ja) 脳症の検出方法
Mcintyre et al. Cariprazine’s efficacy in treating affective symptoms–pooled data from schizophrenia and bipolar depression trials
US10502749B1 (en) Method for patient stratification and drug efficacy monitoring
Magdalinou Diagnostics in Neurodegenerative Parkinsonism
BR102021020428A2 (pt) Potenciais biomarcadores para diagnóstico e prognóstico de transtorno do espectro autístico (tea) e outros transtornos do desenvolvimento em saliva e outras secreções

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120724